Skip to content

Axsome Therapeutics AXSM Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Gross margin92.6%+1.2pp91.4%+1.0pp90.4%+0.8pp89.6%
Operating margin-26.1%+46.6pp-72.7%+12.9pp-85.7%+274pp-359.3%
Net margin-28.7%+45.8pp-74.5%+13.9pp-88.4%+286pp-374%
EBITDA margin-25%+45.9pp-70.9%+12.2pp-83.1%+267pp-350.5%
Free cash flow margin-14.9%+18.5pp-33.4%+20.5pp-53.8%+180pp-234.3%
Returns
Return on equity-252.1%-20.5pp-231.6%-72.4pp-159.2%+140pp-299%-97.5pp
Return on assets-29.1%+20.5pp-49.7%+2.4pp-52%+37.2pp-89.3%+5.9pp
Efficiency
Asset turnover+0.3×0.7×+0.1×0.6×+0.3×0.2×
Inventory turnover2.2×0.0×2.2×-0.5×2.7×
Liquidity
Current ratio1.6×-0.6×2.1×-1.5×3.6×+1.1×2.5×-1.2×
Quick ratio1.5×-0.6×-1.5×3.5×+1.0×2.5×-1.3×
Cash ratio0.9×-0.5×1.4×-1.4×2.8×+0.7×2.1×-1.7×
Leverage
Debt-to-equity2.5×-0.9×3.4×+2.4×+0.1×0.9×-2.3×
Debt-to-assets0.3×0.0×0.3×0.0×0.3×0.0×0.3×-0.3×
Per Share
Book value per share$1.77+49.2%$1.19-71.7%$4.20+56.0%$2.69+549%
Valuation
Market capitalization$9.21B+125%$4.1B+8.9%$3.77B+12.4%$3.35B+131%
Enterprise value$9.1B+129%$3.98B+11.5%$3.57B+9.9%$3.24B+130%
Price / sales14.4×+3.8×10.6×-3.3×13.9×-53.1×67×
Price / book104.3×+32.4×71.9×+52.2×19.7×-10.9×30.6×-62.0×
EV / sales14.3×+3.9×10.3×-2.9×13.2×-51.7×64.9×
Free cash flow yield-1%+2.1pp-3.1%+0.7pp-3.9%-0.4pp-3.5%+4.0pp
Earnings yield-2%+5.0pp-7%-0.7pp-6.4%-0.8pp-5.6%+3.4pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Axsome Therapeutics's profit margins?
Axsome Therapeutics (AXSM) runs a 92.6% gross margin and a -24.4% operating margin, with a -26.6% net margin.
Where do Axsome Therapeutics's ratios come from?
Every ratio is computed from Axsome Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.